Tamarack Advisers’s United Therapeutics UTHR Stock Holding History

Tamarack Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,000	Closed	-$1.34M	–	47
2023 Q1	$1.34M	Buy	+6,000	New	+$1.48M	0.49%	27
2022 Q3	–	Sell	-30,000	Closed	-$7.07M	–	51
2022 Q2	$7.07M	Buy	+30,000	New	+$6.1M	4.09%	8
2022 Q1	–	Sell	-15,000	Closed	-$3.24M	–	59
2021 Q4	$3.24M	Sell	15,000 -50,000	-77%	-$9.82M	1.33%	27
2021 Q3	$12M	Buy	65,000 +3,000	+5%	+$591K	3.79%	8
2021 Q2	$11.1M	Sell	62,000 -38,000	-38%	-$7.24M	3.15%	13
2021 Q1	$16.7M	Sell	100,000 -83,000	-45%	-$13.8M	3.43%	11
2020 Q4	$28.1M	Buy	183,000 +23,000	+14%	+$3.02M	5.86%	3
2020 Q3	$16.2M	Sell	160,000 -15,000	-9%	-$1.65M	4.98%	6
2020 Q2	$21.2M	Buy	175,000 +14,000	+9%	+$1.58M	5.9%	4
2020 Q1	$15.3M	Buy	161,000 +9,600	+6%	+$912K	5.78%	7
2019 Q4	$13.1M	Buy	151,400 +76,400	+102%	+$6.72M	2.99%	15
2019 Q3	$5.98M	Buy	+75,000	New	+$6.04M	1.56%	17

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Tamarack Advisers's UTHR Position: Q2 2023 in Review

Tamarack Advisers sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 6,000 shares — an estimated $1.34M sold.

Tamarack Advisers first reported a position in UTHR in Q3 2019 and held it in 12 quarters. The position peaked at $28.1M in Q4 2020. 475 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Tamarack Advisers reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Tamarack Advisers sold 6,000 United Therapeutics shares in Q2 2023, an estimated $1.34M.
Tamarack Advisers first reported a position in United Therapeutics in Q3 2019 and held it in 12 quarters.
Tamarack Advisers's United Therapeutics position peaked at $28.1M in Q4 2020.
475 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.